EMA accepts regulatory submission for Richter’s combined oral contraceptive
Image by gedeonrichter.com
Pharmaceutical company Gedeon Richter today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for a combined oral contraceptive, containing estetrol (E4) and drospirenone.
Image: Richter.hu
The product is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues, according to a press release by the company.
According to the relevant license agreement, Richter is going to commercialize the product in Europe, Russia, and other CIS countries.
The novel oral contraceptive, developed by Mithra, is a product candidate composed of 15 mg estetrol (E4), a unique native estrogen and 3 mg drospirenone.
Policymakers Cut Central Bank Base Rate by 50 bp to 7.75%
Bulgaria's Household Income, Spending Rise 20% in 2023
Special Effects Expands Portfolio With Acquisition of Creati...
Hungary Launches HUF 15 bln Tourism Sector Support Program
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
